Summary The soluble fragment of E-cadherin protein (S-ECD) is reported to be increased in the peripheral blood of cancer patients. In this study. we investigated the clinical significance of serum S-ECD in 81 patients with gastric cancer. The amount of serum S-ECD was significantly higher in the gastric cancer patients (4735 ± 2310 ng ml-) than in healthy volunteers (2515 ± 744 ng ml-). With the normal range cut-off at average +2 s.d., 67% patients showed abnormally high serum S-ECD levels. This frequency was significantly higher than that of other tumour markers, such as CEA (4.40o) or CAl 9-9 (13.3% Recently. soluble protein fragments of various adhesion molecules. such as intercellular adhesion molecule-1 (ICAM-1) (Reinhardt et al. 1996) . vascular cell adhesion molecule-1 (VCAM-1) (Banks et al. 1993). E-selectin (Schadendorf et al. 1996) . PI integrin (Katayama et al. 1991) and CD44 (Jung et al. 1996). were detected in serum b-the enzv me-link-ed immunosorbent assay (ELISA) method. and their association u-ith disease has been w-ell discussed. Serum S-ECD is reported to be increased in hepatitis (Katayama et al. 1994a (Katavama et al. 1994a: Griffiths et al. 1996. On the other hand. E-cadherin expression in cancer tissues is frequently decreased or showvs no increase (Shiozaki et al. 1991) . This difference between serum S-ECD and E-cadherin expression of cancer cells suggests that S-ECD may be generated in cancer tissues as a consequence of accelerated protein turnover.
Recently. soluble protein fragments of various adhesion molecules. such as intercellular adhesion molecule-1 (ICAM-1) (Reinhardt et al. 1996) . vascular cell adhesion molecule-1 (VCAM-1) (Banks et al. 1993 ). E-selectin (Schadendorf et al. 1996) . PI integrin (Katayama et al. 1991 ) and CD44 (Jung et al. 1996) . were detected in serum b-the enzv me-link-ed immunosorbent assay (ELISA) method. and their association u-ith disease has been w-ell discussed. Serum S-ECD is reported to be increased in hepatitis (Katayama et al. 1994a ). inflammators bowel disease (H Shiozak-i. unpublished obsenration). skin disease (IMatsuvoshi et Received 18 November 1997 Revised 16 March 1998 Accepted 24 March 1998 Correspondence to: J Gofuku al. 1995) and -arious cancers (Katavama et al. 1994a : Griffiths et al. 1996 . On the other hand. E-cadherin expression in cancer tissues is frequently decreased or showvs no increase (Shiozaki et al. 1991) . This difference between serum S-ECD and E-cadherin expression of cancer cells suggests that S-ECD may be generated in cancer tissues as a consequence of accelerated protein turnover.
In this studv. we examined the serum S-ECD level in gastric cancer patients. in comparison A-ith healths s-olunteers. and explored the possibility of serum S-ECD wvorking as a tumour marker. Furthermore. vse demonstrated that serum S-ECD miaht oriainate from cancer tissues based on results from immunoblot and immunohistochemical analssis. These results also gave us important clues towards understanding the mechanism of reduction of E-cadherin expression. which is a characteristic of invasis e and metastatic cancer cells.
MATERIALS AND METHODS Samples
Serum samples were obtained from 20 healthy control subjects and 81 patients with gastric cancer w-ho unders-ent surgers. The patients were 60 men and 21 sAomen w-ith a mean age of 63 years (range 38-88 years). None of them had received anti-cancer therapy before the operation. For 40 out of the 81 patients. serum samples w-ere collected not only before the operation but also at s-eeklv intersals after the operation until 21 post-operatisxe days.
For 44 patients. tissue samples of cancer nests sAere also available for evaluation of E-cadherin expression in cancer tissue. The pathological classification for gastric cancer was based on the International Union Auainst Cancer Classification (UICC). both of which were murine monoclonal antibodies against human E-cadherin with distinct epitopes. The optical density of each well was determined with a microplate reader (Thermo Max. Wako. Japan) at the wavelength of y = 490 nm. Measurement was done in duplicate for each sample and the mean value was used.
Immunohistochemical detection for E-cadherin
Immunostaining for E-cadherin was performed by the avidinbiotin-peroxidase complex method using HECD-I as described previouslv (Shiozaki et al. 1991) . In brief. serial frozen sections (4 im) of cryopreserved tissues were fixed with 3.6% parafonraldehyde in 0.1 M phosphate-buffered saline (PBS) (pH 7.4) for 30 min. Primary antibody was applied and incubated overnight at 40C sequentially. followed by biotinylated anti-mouse IgG and avidin combined in vitro with horseradish peroxidase (Vector. Burlingame. CA. USA). Slides were developed using diaminobenzidine supplemented with 0.02% hydrogen peroxide for 4 min. The sections were counterstained with haematoxylin. dehydrated and mounted.
The E-cadherin expression of cancer cells was compared with that of normal epithelial cells. which always express E-cadherin molecules in the same sample. The cancer cells with staining as strong as that of normal epithelial cells were defined as positive. If the staining was weaker or lost. the cells were defined as negative. The grade of E-cadherin expression of the tumours was evaluated according to the proportion of positive cells. When more than 90%. between 10% and 90% or less than 10% of the cancer cells were positively stained, the tumours were evaluated as preserved (+). reduced (±) and lost (-) respectively. A consecutive section from each specimen was stained with haematoxvlin and eosin for histological evaluation. 
Protein extraction and immunoblot analysis
Samples from cancer tissue and non-cancerous mucosa were divided into two pieces and treated by two different extraction methods. One was homogenized directly in sample buffer containing 2% sodium dodecyl sulphate (50 ami Tris pH 7.5. 150 mm sodium chloride. 1 m-M PMSF. 4 jg ml-' aprotinin. 10 jiJml-' leupeptin) to extract the total tissue proteins. Another piece w as homogenized on ice in PBS containing the same protease inhibitors. but without any detergent. to obtain the soluble components in extracellular spaces. After centrifugation. 3x sample buffer was added to the supernatant. Proteins. applied to each lane. were adjusted to equal concentrations using the BioRad protein assay kit. The resulting lysates were boiled for 5 min in the presence of 5% 2-mercaptoethanol. fractionated by 7.5% polyacrylamide gels and transferred to nitrocellulose sheets. Next. immunoblotting analysis w-as performed with mAb HECD-1. For antibody detection, the blotting detection kit (ECL Western blotting detection reagents. Amersham Life Science. UK) was used.
Statistical analysis
Welch's t-test or Fischer's exact probabilit) test was used to compare the data of the different groups. To analyse the correlation between clinicopathological factors and serum S-ECD levels two-factor factorial ANOVA was used. The data are presented as means ± s.d. Differences of P < 0.05 were considered to be statisticallv significant.
British Joumal of Cancer (1998) 78(8) 1134-10 208) . Thus, serum S-ECD levels in gastric cancer patients were significantly higher than in the healthy control individuals (P<0.0001). In order to confirm the reproducibility, senrm samples were taken again after a 1-week interval from ten patients, and their serum S-ECD amount showed less than 10% difference compared with the first sample. When the normal range was cut off at the average +2 s.d. (4003 ng ml-'), 67% of the gastric cancer patients showed higher serum S-ECD levels than this amount (Figure 1 ). This sensitivity of serum S-ECD in the gastric cancer patients was significantly higher than that of CEA (4.4%) or CA19-9 (13.3%) for 45 randomly chosen patients whose serum levels of CEA and CA19-9 were simultaneously measured in the routine preoperative examination ( Figure 2) .
Next, the serum S-ECD amounts were compared with the histopathological features of the 81 gastric cancer patients based on UICC classification (UICC, 1987) . Serum S-ECD gradually increased with tumour invasion, though the findings were not statistically significant. In addition, there was no significant correlation between the preoperative serum level of S-ECD and lymph node metastasis, distant metastasis and tumour staging (Table 1) .
Tlhe effect of surgical removal of cancer was evaluated by measuring serum S-ECD on post-operative days 7, 14 and 21, in addition to the preoperative day, in 25 randomly chosen patients, who showed serum S-ECD beyond the normal range (mean +2 s.d.). Their serum S-ECD was 6324 ± 1697 ng ml-' at the preoperative stage and gradually decreased after surgical treatment (Figure 3) . The difference was significant between preoperative S-ECD and levels on days 7. 14 and 21. Pre-and post-operative serum S-ECD was also measured in 15 gastric cancer patients who had normal S-ECD concentration. The effects of operation itself on serum S-ECD seemed not so high, because serum S-ECD in these patients remained in the normal range after operation (preoperation 2637 ± 823 ng ml-'; post-operation day 7 1882 + 1063 ng ml-', day 14 2439 ± 1444 ng ml-l and day 21 2151 ± 1270 ng ml-').
Association of serum S-ECD with E-cadherin expression and S-ECD in cancer tissue T'he expressions of E-cadherin in cancer tissues were evaluated by immunohistochemistry in 44 cases out of 81 cancer patients, and classified into the three categories as we described previously (Kadowaki et al, 1994) (Figure 4 ). In 12 patients (27.3%, 12/44). E-cadherin expression was preserved as found in normal epithelium. There were two patterns in the reduction of E-cadherin expression. Dedine of serum S-ECD concentraion after removal of primary umour by surgery. Twenty-fe pafients wit high senm S-ECD were foowed unti 3 weeks after operation and average and s.d. of serun S-ECD are shown. Note serunm S-ECD levs were after operation (P < 0.0001) E-cadherin partially reduced (±) tumours which consisted of a mixture of E-cadherin-positive and -negative cells. The rest of the patients were classified as E-cadherin lost (-) tumours, in which E-cadherin was completely lost or weakly expressed in the cytoplasm. When the immunohistochemistry was compared with serum S-ECD, E-cadherin partially reduced (±) tumours showed A B higher levels of serum S-ECD (6249 ± 1592 ng ml-') than the preserved (+) (3353 ± 1902 ng ml-') or lost (-) tumours (3402 ± 1659 ng ml-') ( Figure 5 ).
Representative tumours of these three patterns were subjected to Western blot analysis and the results are shown in Figure 6 . Fulllength human E-cadhern and S-ECD were recognized at 120 kDa and 80 kDa, respectively, in total tissue extrct with 2% sodium dodecyl sulphate. The band around 100 kDa is considered to be another degraded form of E-cadherin, which is cleaved in the cytoplasm and not detected outside the cells (Covault et al, 1991) .
Immunohistochemical expressions of E-cadherin were consistent with the band of 120-kDa E-cadherin in normal squamous epithelium and three different types of cancer tissues. S-ECD was observed strongly in E-cadherin partially reduced (±) tumour and preserved (+) tumour, and faindly observed in normal epithelium and E-cadherin lost (-) tumour. The proportion of S-ECD against 120-kDa E-cadherin was highest in E-cadherin partially reduced (±) tumour. S-ECD was concentrated in the extracellular fraction, which can be obtained by mild homogenization without any detergents, and this fraction did not contain full-length E-cadherin, which is bound to the cell membrane or exists in the cytosol. S-ECD in this fraction was highest in E-cadherin partially reduced (±) tumour, and lowest in normal epithelium and E-cadherin lost (-) tumour. Thus, the amounts of S-ECD in the extracellular space of cancer tissues were similar to those in peripheral blood detected by ELISA.
E-cadherin is a 120-kDa transmembrane glycoprotein which plays a central role in intercellular adhesion of epithelial cells (Takeichi, 1991) . In the conditioned medium of cultured epithelial cells, soluble fragments of E-cadherin (S-ECD) were detected at 80-84 kDa and increased by tiypsin treatment (Ozawa et al, 1990 Figure 5 Companson between E-cadherin expression in the pnmary site and S-ECD in peripheral blood. Serum S-ECD was significantly higher in the patients with E-cadherin reduced (±) tumours than in the patients with other expression pattems or healthy volunteers (P < 0.0001) al. 1993) . CAI 9-9 is sialyl Lewis A antigen and a ligand of Eselectin (Majuri et al. 1992) . SLX is also included in this group (Phillips et al. 1990 ). The benefits of these proteins as tumour markers are that thev haxe hiah specificitv for organs and malignancies (Kax-ahara et al. 1985 : Civardi et al. 1986 ). In addition.
w-hen thev are present. their amounts are usually large enough to be easilv distinouished from those in the normal range. How-ever.
cancer cells do not always ox-erexpress these proteins and. therefore. the sensitixitv is sometimes not so high. especially in gastric cancers (Staab et al. 1985) .
A second group of adhesion molecules is not specific for cancer cells. but usually expressed in normal and cancerous tissue.
Ho%vexer. their escape into the sN stemic circulation is stimulated in cancer patients. probablv because of acceleration of turnoxer or degradation of the protein. E-selectin (Schadendorf et al. 1996) . ICAM-I (Reinhardt et al. 1996) . VCAM (Banks et al. 1993 ). CD44 (Jung et al. 1996) and laminin (Brocks et al. 1986 : Katavama et al. 1992 haxe been included in this categ!ory. as has the S-ECD of this studv. The sensitixity of S-ECD in gastric cancer patients wxas 67%7. which is significantly higher than that of CEA or CAl9-9.
Moreox er. this X alue is also higher than that of other proteins of the same group. including ICAM-1 in colon cancer (Reinhardt et al. 1996) or NCAM in lung cancer (Ledermann et al. 1994) .
Clinical application of these proteins as a tumour marker remains difficult. because they are not cancer or organ specific. In particular. inflammatory disease is associated xx-ith the increase in the amount of serum of these molecules. In the case of S-ECD.
inflammation of E-cadherin-rich organs such as lixer (Katayama et al. 1994a ). skin (Furukaxxa et al. 1994) (Nigam et al. 1993 ) than in gastric cancers (Oka et al. 1992 ) (preserxed type 71 7c xs. 421c).
In order to find support for our hypothesis that tumour characteristics related to E-cadherin expression affects the serum S-ECD amount. xxse compared the serum S-ECD amount with the immunohistochemical expression of E-cadherin in cancer tissues. In a previous study. we had noticed that there were tmo different patterns in the reduction of E-cadhenrn expression in gastric cancer. In the present study. we classified the tumours into Ecadherin preser-ed (+). partiallv reduced (±) and lost (-) tvpes. What is notable is that partiall1 reduced (±) tumours showed higher serum S-ECD levels than preserved (+) tumours or losttumours. In addition. E-cadherin partially reduced 1±) tumours had more S-ECD than the others. when the cancer tissue Awas subjected to extraction without detergent. In the previous study. both E-cadherin partially reduced (±) and lost (-) tumours showed similar aggressive behaviour. regarding tumour invasion and metastasis (Oka et al. 1992 ). Thus. as serum S-ECD is not increased in both E-cadherin preserved (+) and lost (-) tumours.
which have distinct tumour characteristics. S-ECD might not affect the clinicopathological features.
As possible mechanisms for E-cadherin reduction. allelic loss (Vessev et al. 1995) . gene mutation (Becker et al. 1994 ) and DNA methvlation in promoter lesions (Graff et al. 1995 : Yoshiura et al. 1995 ) have been reported. These genomic disorders in stem cells might be responsible for homogeneous E-cadherin reduction. but they cannot explain the heterogeneity of E-cadherin expression which is sometimes observed even in a small colony. Transcriptional regulation might be another important pathway for regulating E-cadherin expression. in which g-rowth factors (Caulin et al. 1995) . hormones (Carruba et al. 1995) (Ozawa et al. 1990 ). Thus. identifying the E-cadherin protease in cancer tissue miaht be necessarv in the future to understand the E-cadherin reduction and S-ECD production in cancers in vivo. The detection of S-ECD has many possible applications in both basic and clinical research. Mass screenina studies of serum S-ECD can be done to establish the specificity of increased serum S-ECD for cancer patients and to demonstrate the possibility of clinical application of serum S-ECD measurement. In addition. S-ECD in cancer tissue is associated with E-cadherin reduction and tumour invasion. For example. we have found that more S-ECD is detected in the invadinc area than in the centre of the tumour (unpublished observation). Thus. S-ECD is not just a degraded protein fragment of E-cadherin. If its mechanism of production can be revealed. S-ECD may serve as an important tool against cancer.
